• Suspended

NCT03218683: Phase 1/2: Study of AZD5991 Alone or with Venetoclax in Relapsed Hem Malignancies

Updated: Jun 15

NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.


azd5991

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.


This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies Part 1 of the study is monotherapy dose escalation. Closed November 2020 Part 2 of the study is monotherapy expansion groups for relapsed/refractory chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM). Closed November 2020 Part 3 is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in subjects with relapsed/refractory AML


Sponsor

AstraZeneca


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT03218683

Official Title: A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

First Posted: July 14, 2017


Click here for details on ClinicalTrials.gov

 

Drug: AZD5991

Drug: AZD5991 + Venetoclax

 

Mcl-1 Inhibitor AZD5991 (Code C137989)

Mcl-1 Inhibitor AZD5991

AZD-5991

AZD5991

Mcl-1 Inhibitor AZD5991

MCL1 Inhibitor AZD5991


Venetoclax (Code C103147)

4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide

ABT-0199

ABT-199

ABT199

GDC-0199

RG7601

Venclexta

Venclyxto

Venetoclax

VENETOCLAX

 

Nat Commun; 2018 Dec

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

https://pubmed.ncbi.nlm.nih.gov/30559424/

 

Locations

United States, California

United States, Colorado

United States, Georgia

United States, Massachusetts

United States, Missouri

United States, New York

United States, Ohio

United States, Oregon

United States, Tennessee

United States, Texas










Posts Archive